Body weight and composition endpoints in cancer cachexia clinical trials: Systematic Review 4 of the cachexia endpoints series

作者：Leo R. Brown, Mariana S. Sousa, Michael S. Yule, Vickie Elaine Baracos, Donald C. McMillan, Jann Arends, Trude Rakel Balstad, Asta Bye, Olav Faisal Dajani, Ross Dean Dolan, Marie Fallon, Christine Greil, Marianne Jensen Hjermstad, Gunnhild Jakobsen, Matthew Maddocks, James J. McDonald, Inger Ottestad, Iain Phillips, Judith Sayers, Melanie Rae Simpson, Ola Magne Vagnildhaug, Tora S. Solheim, Barry J. A. Laird, Richard J.E. Skipworth, the Cancer Cachexia Endpoints Working Group · 发表于：Journal of Cachexia Sarcopenia and Muscle · 年份：2024 · DOI：10.1002/jcsm.13478 · 被引用次数：41 · 研究领域：Nutrition and Health in Aging、Body Composition Measurement Techniques、Vitamin D Research Studies

Significant variation exists in the outcomes used in cancer cachexia trials, including measures of body composition, which are often selected as primary or secondary endpoints. To date, there has been no review of the most commonly selected measures or their potential sensitivity to detect changes resulting from the interventions being examined. The aim of this systematic review is to assess the frequency and diversity of body composition measures that have been used in cancer cachexia trials. MEDLINE, Embase and Cochrane Library databases were systematically searched between January 1990 and June 2021. Eligible trials examined adults (≥18 years) who had received an intervention aiming to treat or attenuate the effects of cancer cachexia for >14 days. Trials were also of a prospective controlled design and included body weight or at least one anthropometric, bioelectrical or radiological endpoint pertaining to body composition, irrespective of the modality of intervention (e.g., pharmacological, nutritional, physical exercise and behavioural) or comparator. Trials with a sample size of <40 patients were excluded. Data extraction used Covidence software, and reporting followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidance. This review was prospectively registered (PROSPERO: CRD42022276710). A total of 84 clinical trials, comprising 13 016 patients, were eligible for inclusion. Non-small-cell lung cancer and pancreatic cancer were studied most ...